Table 1.

Baseline characteristics

	DOAC (n = 48)	Warfarin (n = 107)	p value
Time on therapy (months)
Cumulative	810	5637
Median	11.0	46.0
Range	0.5–68.1	0.7–209.9
Age at therapy start (years)	29.5 (26–37)	23 (19–31)	< 0.01
Body surface area	1.75 (1.64–1.93)	1.76 (1.62–1.93)	0.90
Body mass index	23.68 (21.22–28.93)	23.39 (20.48–27.53)	0.55
Female	22 (45.8)	52 (48.6)	0.75
Predominant systemic ventricle anatomy
Left	34 (70.8)	78 (72.9)	0.46
Right	7 (14.6)	20 (18.7)
Unspecified	7 (14.6)	9 (8.4)
Fontan type
AP	10 (20.8)	23 (21.5)	0.28
LT	22 (45.8)	55 (51.4)
ECC	13 (27.1)	28 (26.2)
Other	3 (6.3)	1 (0.9)
Indication for anticoagulation
Arrhythmia	24 (50.0)	43 (40.2)	< 0.01
Thrombosis	11 (22.9)	39 (36.4)
Procedure*	8 (16.7)	1 (0.9)
Other†	5 (10.4)	10 (9.3)
Empiric‡	0	14 (13.1)
Other agents used
None	41 (85.4)	72 (67.3)	0.06
Aspirin, Clopidogrel, NSAID	7 (14.6)	34 (31.8)
Enoxaparin	0	1 (0.9)

If not expressly stated, values are median (interquartile range) or n (%).

^*Procedure = coiling, stents, antiarrhythmia, cardioversion;

^†Other = patent fenestration, right-to-left shunt, cyanosis, decreased ventricular function, prosthetic valve, hypercoagulability;

^‡Empiric = Fontan physiology prophylaxis, not documented. Of the 48 patients on a DOAC, 10 were exclusively treated with a DOAC, 25 were at some point on warfarin, and 26 were at some point on aspirin. Of the 107 patients on warfarin, 64 were treated exclusively with warfarin, 25 were at some point on a DOAC, and 31 were at some point on aspirin. Of the 180 patients on aspirin, 136 were exclusively treated with aspirin, 26 were at some point on a DOAC, and 31 were at some point on warfarin. Thirteen patients were, at different points, treated with all three therapies